Fox Run Management L.L.C. Acquires New Position in Hims & Hers Health, Inc. $HIMS

Fox Run Management L.L.C. acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 9,721 shares of the company's stock, valued at approximately $287,000.

Several other large investors have also bought and sold shares of the business. Regal Partners Ltd acquired a new position in Hims & Hers Health in the first quarter valued at approximately $885,000. HighTower Advisors LLC acquired a new stake in Hims & Hers Health in the first quarter worth $482,000. Nuveen LLC acquired a new stake in Hims & Hers Health in the first quarter worth $58,403,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Hims & Hers Health by 3.7% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,216,499 shares of the company's stock worth $35,948,000 after purchasing an additional 43,525 shares during the period. Finally, National Bank of Canada FI raised its holdings in Hims & Hers Health by 48.4% in the first quarter. National Bank of Canada FI now owns 4,436 shares of the company's stock worth $131,000 after purchasing an additional 1,446 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their target price for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Finally, Truist Financial lowered their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $42.1760 on Wednesday. The stock has a market cap of $9.53 billion, a P/E ratio of 52.72, a P/E/G ratio of 2.86 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The company has a fifty day moving average price of $52.47 and a two-hundred day moving average price of $45.75. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company's revenue was up 72.6% on a year-over-year basis. During the same quarter last year, the business earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the sale, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 2,572 shares of Hims & Hers Health stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $51.64, for a total transaction of $132,818.08. Following the completion of the sale, the insider owned 153,021 shares of the company's stock, valued at approximately $7,902,004.44. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,273,034 shares of company stock valued at $66,425,573 in the last three months. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.